CV Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

The following summarizes activity related to the Company's stock options (in thousands, except per share data):


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding - December 31, 2020	25,225	$	0.48	5.7	$	2,186
Granted	6,900	0.54		—	—
Exercised	(2)	0.26		—	—
Forfeited	(1,960)	0.58		—	—
Outstanding - December 31, 2021	30,163	0.49		5.5	—

Exercisable - December 31, 2021	24,240	0.48		4.6	—
Vested or expected to vest - December 31, 2021	30,163	$	0.49	5.5	$	—

Fair Value Assumptions

The following table presents the weighted average grant date fair value of stock options granted and the weighted-average assumptions used to estimate the fair value on the date of grant using the Black-Scholes valuation model:


	For the years ended December 31,
	2021	2020
Volatility	133.2%	132.9%
Risk-Free Interest Rate	0.9%	0.5%
Expected Term (in years)	5.61	5.33
Dividend Rate	0.0%	0.0%
Fair Value Per Share on Grant Date	$0.48	$0.36